Clinical trial
Role of Pegylated Interferon in Combination With Direct Acting Antivirals (DAAs) to Cure Hepatitis C As Soon As Possible (ASAP) - Hepatitis C [ASAP-C]
NCT03480932 is registered in ClinicalTrials.gov with Johns Hopkins Bloomberg School of Public Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Role of Pegylated Interferon in Combination With Direct Acting Antivirals (DAAs) to Cure Hepatitis C As Soon As Possible (ASAP) - Hepatitis C [ASAP-C]
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- February 2, 2018
- Completion date
- November 2, 2018
- Enrollment
- 150 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.